Identification

Instrument name
PHARMANUTRA
Symbol
PHN
ISIN code
IT0005274094
Code LEI
815600F8217BC7733697
Exchange / Market
Euronext
Trading location
Milan
ICB
20103015 Pharmaceuticals

Operation

IPO date
di 15/12/2020
IPO type
Transfer

Bedrijfsprofiel

PharmaNutra S.p.A. specializes in the research, development and marketing of nutraceutical products. Also, the group develops an activity involving the manufacturing and sales of medical devices and pharmaceuticals. The group's activity is organized around 3 product families:
  • food supplements: iron, folic acids, vitamins, omega 3 and microelement-based products sold under SiderAL, Gestalys, Bonecal, Novomega and Dikappa2 brands, intended for the treatment of anemia and food deficit, and the prevention of cardiovascular disorders. Additionally, PharmaNutra S.p.A. offers anti-inflammatory products for joint and musculoskeletal pain relief (Cetilar);
  • medical devices, generic drugs and OTC products (Junia Pharma). Moreover, the group markets infant nutritional supplements;
  • bioactive ingredients and pharmaceutical active ingredients (Alesco): for the pharmaceutical, agri-food and nutraceutical industries.
Its products are marketed through direct sales (63.4% of net sales), partner distributors (31.6%) and other (5%). Net sales are distributed geographically as follows: Italy (67.8%), Europe (16.9%), Middle East (10.6%), South America (1.9%), Far East (1.5%) and other (1.3%).

Bron: Cofisem - laatste update: 17 Sep 2024
Bestuurders
Chairman and Chief Executive Officer Andrea Lacorte
Chief Executive Officer Roberto Lacorte
Chief Operating Officer Carlo Volpi
Bron: Cofisem - laatste update: 17 Sep 2024
Kerncijfers
Millenium 2023 2022 2021 2020 2019
Net sales 100.202 82.724 68.114 56.449 53.624
Income from ordinary activities 100.202 82.724 68.114 56.449 53.624
Operating income 23.360 23.040 18.691 13.216 12.204
Cost of financial indebtedness net 482 -68 -99 -61 -28
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income 12.832 15.048 13.771 14.072 8.454
Net income (Group share) 12.832 15.048 13.771 14.072 8.454
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards IFRS IFRS IFRS IFRS IFRS
Bron: Cofisem - laatste update: 17 Sep 2024
Aandeelhoudersinformatie
Andrea Lacorte 31,38 %
Roberto Lacorte 0,15 %
Azimut Libera Impresa SGR SpA 3,37 %
Beda S.r.l. 10,48 %
Norges Bank 3,46 %
Rlh S.r.l. 22,98 %
Bron: Cofisem - laatste update: 17 Sep 2024